GC
CASI

Guggenheim Capital’s CASI Pharmaceuticals CASI Stock Holding History

Guggenheim Capital’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,095
Closed -$46K – 2403
2018
Q1 		$46K Buy
1,095
+7
+0.6% +$261 ﹤0.01% 2711
2017
Q4 		$35K Sell
1,088
-136
-11% -$3.69K ﹤0.01% 2646
2017
Q3 		$22K Buy
+1,224
New +$14.3K ﹤0.01% 2744
2014
Q2 		– Sell
-1,295
Closed -$24K – 3207
2014
Q1 		$24K Buy
1,295
+294
+29% +$5.56K ﹤0.01% 3213
2013
Q4 		$17K Buy
+1,001
New +$16.9K ﹤0.01% 3144

Other funds holding CASI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Guggenheim Capital's CASI Position: Q2 2018 in Review

Guggenheim Capital sold out of CASI Pharmaceuticals (CASI) in Q2 2018, closing a stake of 1,095 shares — an estimated $46K sold.

Guggenheim Capital first reported a position in CASI in Q4 2013 and held it in 5 quarters. The position peaked at $46K in Q1 2018. 57 funds tracked by Wall St. Rank hold CASI as of Q2 2018.

  • Guggenheim Capital reported no remaining CASI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 1,095 CASI Pharmaceuticals shares in Q2 2018, an estimated $46K.
  • Guggenheim Capital first reported a position in CASI Pharmaceuticals in Q4 2013 and held it in 5 quarters.
  • Guggenheim Capital's CASI Pharmaceuticals position peaked at $46K in Q1 2018.
  • 57 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.